Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

Janssen Biotech announced new five-year data from three pivotal Phase 3 studies evaluating Simponi (golimumab) 50mg administered subcutaneously once every four weeks in the treatment of moderately to ...

The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis. Golimumab-sldi ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Simponi is also prescribed to treat ulcerative colitis in adults. And Simponi Aria is also prescribed to treat PsA and polyarticular juvenile idiopathic arthritis in some children. Simponi and Simponi ...

First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

Simponi works by blocking tumor necrosis factor (TNF), which plays an important role in causing abnormal inflammatory and immune responses. Previously approved to treat rheumatoid arthritis, psoriatic ...

The CHMP positive opinion was based on the findings from the GO-AHEAD study, which demonstrated significant clinical improvement in patients with active nr-axial SpA treated with golimumab, compared ...

Sometimes follow-on drugs are flubs that would have been better put in the trash can, but I don't think that'll be the case for Johnson & Johnson's (NYSE:JNJ) Simponi: it was approved on Friday for ...